GlassScriptPhysician profile
Timothy L Thomason
NPI 1972665370
$1,325.54
in general payments reported to CMS, 2019-2025
19 companies · $1,104 in 2025
The $1,104 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $22.60 · 2022: $21.91 · 2023: $98.15 · 2024: $78.63 · 2025: $1,104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,281.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $336.91 | 2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $164.66 | 2023-2025 | Breztri, Farxiga |
| Cequr Corporation | $146.59 | 2025 | Cequr Simplicity |
| Dexcom, INC. | $101.30 | 2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $96.26 | 2025 | Minimed 780g |
| Bayer Healthcare Pharmaceuticals INC. | $84.80 | 2025 | |
| Axsome Therapeutics, INC. | $57.58 | 2025 | Auvelity |
| Novo Nordisk INC | $52.40 | 2025 | Rybelsus, Ozempic |
| Boston Scientific Corporation | $40.15 | 2024 | Rezum Generator |
| Xeris Pharmaceuticals, INC. | $39.46 | 2025 | Gvoke Hypopen |
| Abbvie INC. | $34.11 | 2025 | |
| Glaxosmithkline, LLC. | $25.61 | 2025 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.91 | 2025 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.31 | 2025 | Caplyta |
| Genentech USA, INC. | $22.60 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $21.93 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $21.91 | 2022 | |
| Shield Therapeutics INC | $16.55 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.50 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Thomason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.